within Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX03_Radium223raDichloride;

model Radium223raDichloride
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.277777777777778e-06,
    adminDuration = 600,
    adminMass = 55 / 1000000,
    adminCount = 1,
    Vd = 0.151,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Radium223raDichloride</td></tr><tr><td>ATC code:</td><td>V10XX03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>55</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>151</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15.4</td><td>liters/hour</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Radium-223 dichloride is a radiopharmaceutical agent used in the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. It is administered intravenously and delivers targeted alpha radiation to bone metastases sites. The drug is approved and used clinically under the trade name Xofigo.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with castration-resistant prostate cancer, based on population PK data from clinical trials.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V10XX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Radium223raDichloride;
